Economic impact of mortality risk reduction with first-line imatinib (IM) versus interferon-α (IFN) in patients newly diagnosed with chronic phase (CP) chronic myeloid leukemia (CML) under the Brazilian public healthcare system perspective over a 5-year period

Fabio Mataveli,Alessandra Calabró,Wellington Mendes,Denizar Vianna,Pedro Enrique Dorlhiac-Llacer,Ricardo Bigni,Vania Hungria

Economic impact of mortality risk reduction with first-line imatinib (IM) versus interferon-α (IFN) in patients newly diagnosed with chronic phase (CP) chronic myeloid leukemia (CML) under the Brazilian public healthcare system perspective over a 5-year period

2016

Fabio Mataveli
Alessandra Calabró
Wellington Mendes
Denizar Vianna
Pedro Enrique Dorlhiac-Llacer
Ricardo Bigni
Vania Hungria

17068 Background: Patients receiving imatinib had a significant survival advantage compared with patients receiving IFN therapy (Roy et al. Blood 2006; Kantarjian et al. Blood 2006). Although reimb...

Keywords:

Pathology
Oncology
Health care
Interferon
Imatinib
Myeloid leukemia
Internal medicine
Medicine
in patient
interferon α
survival advantage
newly diagnosed
first line
public healthcare

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations